Under CETA there will be an increase in the length of the patent protection in Canada. That's been discussed. The reason why that could increase costs is that generics, which are much lower priced, will be delayed coming into the Canadian market.
As indicated earlier this week in the appearance of the Canadian chief negotiator, the Canadian position that we understand is that Canada should not agree to further intellectual property extensions as part of the Trans-Pacific Partnership agreement. Canada already has intellectual property provisions in pharmaceuticals that go well beyond many of the trading partners we're negotiating with, so we are confident and we support the position that there should be no further extension of patents in Canada. If that is the case then of course there shouldn't be new and extra costs for the Canadian pharmaceutical system.